Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AttIL12 T-cells |
| Synonyms | |
| Therapy Description |
AttIL12 T-cells are T-lymphocytes engineered to express membrane-anchored IL12 targeted to cell-surface vimentin (CSV), which potentially induce cytotoxicity in CSV-expressing tumor cells, enhance antitumor immune response, and inhibit tumor growth (PMID: 35027427). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AttIL12 T-cells | AttIL12 armed T cells|attIL12-expressing T-cells | AttIL12 T-cells are T-lymphocytes engineered to express membrane-anchored IL12 targeted to cell-surface vimentin (CSV), which potentially induce cytotoxicity in CSV-expressing tumor cells, enhance antitumor immune response, and inhibit tumor growth (PMID: 35027427). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06474676 | Phase I | AttIL12 T-cells Cyclophosphamide | T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. | Recruiting | USA | 0 |